These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 3705598)

  • 1. In vivo platelet activity and lipoprotein patterns in coronary artery disease.
    Goubran F; Maklady F; Saad M; el-Ashry M
    Wien Klin Wochenschr; 1986 Apr; 98(7):209-11. PubMed ID: 3705598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma lipoprotein pattern and decreased platelet function in type V hyperlipoproteinemia.
    Aviram M; Brook JG
    Isr J Med Sci; 1985 Nov; 21(11):898-904. PubMed ID: 4077486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and late results of coronary artery bypass in patients with hyperlipoproteinemia.
    Hanson EC; Levine FH; Adzick NS; Lees RS; Daggett WM; Austen WG; Buckley MJ
    J Thorac Cardiovasc Surg; 1980 Mar; 79(3):372-80. PubMed ID: 6965512
    [No Abstract]   [Full Text] [Related]  

  • 4. [Apolipoproteins A-1 and B of the blood plasma and apolipoproteins A-1 of 2 high-density lipoprotein subclasses in ischemic heart disease patients with various lipoprotein spectra].
    Metel'skaia VA; Perova NV; Chernysheva NP; Kurdanov KhA; Polesskiĭ VA
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1983; 6(1):83-9. PubMed ID: 6407489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
    Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
    Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H; Bojanovski D
    Artery; 1980; 8(2):171-8. PubMed ID: 7458684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
    Hutt V; Klör HU; Wechsler JG; Ditschuneit H
    J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased plasma fibrinogen and platelet-aggregates in type II hyperlipoproteinaemia.
    Lowe GD; Drummond MM; Third JL; Bremner WF; Forbes CD; Prentice CR; Lawrie TD
    Thromb Haemost; 1980 Feb; 42(5):1503-7. PubMed ID: 7368154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet activity in vivo in hyperlipoproteinemia--importance of combined hyperlipidemia.
    Bröijersén A; Hamsten A; Eriksson M; Angelin B; Hjemdahl P
    Thromb Haemost; 1998 Feb; 79(2):268-75. PubMed ID: 9493574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Platelet half-life in patients with primary hyperlipoproteinemia type IIa, IIb, and IV according to Fredrickson with and without clinical signs of atherosclerosis].
    Jäger E; Sinzinger H; Widhalm K; Kaliman J; Höfer R
    Wien Klin Wochenschr; 1982 Sep; 94(16):421-5. PubMed ID: 7147981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Platelet aggregation in whole blood and prostacyclin in hyperlipemia types II and IV].
    Craveri A; Lanfredini M; Citella C; Barbesti S; Tempesta A; Gallo E
    Minerva Med; 1988 May; 79(5):349-54. PubMed ID: 3374826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyperlipoproteinemia, HDL-cholesterol and arteriosclerosis indices].
    Herrmann W; Reuter W
    Z Gesamte Inn Med; 1982 Dec; 37(24):830-3. PubMed ID: 6963524
    [No Abstract]   [Full Text] [Related]  

  • 14. [The effect of lovastatin therapy on the dynamics of the clinical state of patients with ischemic heart disease and hyperlipoproteinemia].
    Zhukova IM; Iurenev AP; Pomerantsev EV; Martynov AA; Shabalkin BV; Titov VN; Shimbaeva NA; Kotkina AA; Bochkova EI; Lediashova GA
    Ter Arkh; 1990; 62(8):130-3. PubMed ID: 2274859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gemfibrozil in the treatment of hyperlipoproteinemias].
    Monova D; Petrova V; Belovezhdov N
    Vutr Boles; 1991; 30(2):56-8. PubMed ID: 1891900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biochemical diagnosis of hereditary hyperlipoproteinemias].
    Tvorogova MG; Rozhkova TA; Alidzhanova KhG; Semenova OA; Sobolev AV; Kukharchuk VV; Titov VN
    Ter Arkh; 1998; 70(4):9-15. PubMed ID: 9612894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Blood lipids and lipoproteins in patients with ischemic heart disease without hyperlipoproteinemia].
    Tokarskaia ZB; Tel'nov VI
    Ter Arkh; 1982; 54(5):43-6. PubMed ID: 7101185
    [No Abstract]   [Full Text] [Related]  

  • 19. [Platelet aggregation in hyperlipoproteinemias].
    Calabrese S; Da Col PG; Giansante C; Morgante O; Cattin L
    Minerva Med; 1982 May; 73(22):1541-6. PubMed ID: 7088380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
    Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
    Artery; 1985; 12(6):363-81. PubMed ID: 4051756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.